Introduction {#s1}
============

Genomic instability is a fundamental feature of human cancer, and DNA repair defects resulting in impaired genome maintenance promote pathogenesis of many human cancers ([@bib18]; [@bib15]). In prostate cancer, structural genomic rearrangements, including translocations (e.g., *TMPRSS2-ERG*) and copy number aberrations (e.g., 8q gain, 10q23/*PTEN* loss) are a key mechanism driving tumorigenesis ([@bib34]; [@bib11]; [@bib32]; [@bib37]; [@bib22]; [@bib12]; [@bib6]).

Whole genome sequencing (WGS) has allowed an unprecedented insight into the alterations underlying cancer. Recently, WGS of treatment naive, clinically localized prostate cancer revealed a striking abundance of genomic rearrangements, in some samples comparable to the number of rearrangements in metastatic prostate cancer ([@bib3]). Furthermore, the type (intrachromosomal vs interchromosomal) and complexity of rearrangements in these tumors shows remarkable heterogeneity, potentially suggesting distinct mechanisms of instability in different molecular classes of prostate cancer. However, somatic alterations underlying these phenomena remain unexplained.

Mutations in *SPOP* (Speckle-type POZ protein) occur in around 10% of prostate cancers and represent the most common non-synonymous mutations in primary prostate cancer ([@bib4]). *SPOP* mutations define a distinct molecular class of prostate cancer; they are mutually exclusive with ETS rearrangements but display distinct patterns of somatic copy number alterations (SCNAs) ([@bib4]).

Here, we investigated somatic alterations associated with genomic rearrangements in prostate cancer. We show that *SPOP* mutation is an early event specifically associated with increased intrachromosomal genomic rearrangements. Mechanistically, in vitro and in vivo data suggest that SPOP participates in repair of DNA double strand breaks (DSB), and *SPOP* mutation impairs homology-directed repair (HDR), instead promoting error-prone non-homologous end joining (NHEJ).

Results {#s2}
=======

To nominate somatic events associated with structural genomic rearrangements in clinically localized prostate cancer, we examined WGS data from 55 treatment naive prostate cancers ([@bib3]) ([Figure 1A](#fig1){ref-type="fig"}). This analysis revealed a bimodal distribution, with a more common, 'low-rearrangement' population, and a less frequent 'high-rearrangement' population primarily driven by intrachromosomal rearrangements (deletions, inversions, and tandem duplications), rather than balanced interchromosomal rearrangements ([Figure 1B](#fig1){ref-type="fig"}). We then analyzed the association between recurrent somatic alterations (point mutations and SCNAs) and number of rearrangements ([Figure 1C](#fig1){ref-type="fig"}; [Figure 1---figure supplements 1, 2](#fig1s1 fig1s2){ref-type="fig"}). Several recurrent deletions, primarily on chromosomes 5q and 6q, were significantly associated with intrachromosomal genomic rearrangements ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), and these were completely distinct compared to alterations associated with interchromosomal rearrangements ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Among recurrent point mutations, only a single lesion---mutation in *SPOP*---was significantly associated with increased rearrangements ([Figure 1C](#fig1){ref-type="fig"}). Consistent with increased intrachromosomal rearrangements, SCNA analysis revealed that *SPOP* mutant prostate cancers showed significantly higher total copy number alteration burden ([Figure 1D](#fig1){ref-type="fig"}).10.7554/eLife.09207.003Figure 1.SPOP mutant prostate cancer displays increased genomic rearrangements.(**A**) Distribution analysis of genomic rearrangements from 55 clinically localized prostate cancers distinguishes two subpopulations. (**B**) Increased total rearrangements are driven by intrachromosomal rather than interchromosomal rearrangements. 55 clinically localized prostate cancers ordered (right to left) according to total rearrangements; numbers of intrachromosomal and interchromosomal rearrangements are displayed. (**C**) Association of recurrent point mutations with intrachromosomal rearrangements. X-axis shows (−log10) p-value. (**D**) SPOP mutant prostate cancers harbor increased total somatic copy number aberration (SCNA) burden. The fraction of altered genome, partitioned into bins covering a range from \<0.01 to ≥0.5, is shown as a histogram for SPOP WT and SPOP mutant tumors. Inset: the percentage of altered genome is significantly increased in SPOP mutant prostate cancers (p = 0.0016, two-sample Wilcoxon-Mann-Whitney test). (**E**) Frequency of somatic copy number alterations in 430 clinically localized prostate cancers. SPOP-mutant cancers (orange) and SPOP-wild-type tumors (gray). Length of bars indicates the frequency of copy number alterations. (**F**) Clonality of selected alterations associated with genomic rearrangements, in 430 clinically localized prostate cancers.**DOI:** [http://dx.doi.org/10.7554/eLife.09207.003](10.7554/eLife.09207.003)10.7554/eLife.09207.004Figure 1---figure supplement 1.Association of recurrent SCNAs with intrachromosomal rearrangements.Cytobands undergoing deletion are labeled blue. X-axis shows (−log~10~) p-value.**DOI:** [http://dx.doi.org/10.7554/eLife.09207.004](10.7554/eLife.09207.004)10.7554/eLife.09207.005Figure 1---figure supplement 2.Association of recurrent SCNAs or point mutations with interchromosomal rearrangements.Cytobands undergoing deletion are labeled blue, PM refers to recurrent point mutations. '*ERG* rearrangement' was determined by FISH assay. X-axis shows (−log~10~) p-value.**DOI:** [http://dx.doi.org/10.7554/eLife.09207.005](10.7554/eLife.09207.005)10.7554/eLife.09207.006Figure 1---figure supplement 3.Genomic view of CHD1 and MAP3K7 areas in 430 prostate cancers sorted by SPOP mutation status.Blue indicates genomic deletion.**DOI:** [http://dx.doi.org/10.7554/eLife.09207.006](10.7554/eLife.09207.006)10.7554/eLife.09207.007Figure 1---figure supplement 4.Genomic burden of three subset of prostate cancers defined by the aberration state of SPOP, CHD1, and MAP3K7.No increased signal is detected with respect to the SPOP class.**DOI:** [http://dx.doi.org/10.7554/eLife.09207.007](10.7554/eLife.09207.007)10.7554/eLife.09207.008Figure 1---figure supplement 5.Evolution graphs built from prostate cancer sequencing data.These data were generated based on a previously published algorithm to build tumor evolution paths ([@bib3]; [@bib26]).**DOI:** [http://dx.doi.org/10.7554/eLife.09207.008](10.7554/eLife.09207.008)

*SPOP* mutation frequently co-occurs with specific SCNAs, designating a molecular class of prostate cancer ([@bib4]; [@bib7]) ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). Independent analysis of SCNAs from three publicly available data sets comprising 430 tumors ([@bib3]; [@bib4]; [@bib30]), including 47 *SPOP* mutant prostate cancers, confirmed that the rearrangement-associated deletions ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) were those enriched in *SPOP* mutant prostate cancer ([Figure 1E](#fig1){ref-type="fig"}). When individually comparing *SPOP* mutations and associated deletions (*CHD1* and *MAP3K7*), we did not observe significant differences in SCNA burden for any one lesion ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). Analysis of clonality ([@bib3]; [@bib26]) of specific lesions showed that *SPOP* mutations were highly clonal compared to loci in the associated deletion peaks, supporting that *SPOP* mutations precede deletions ([Figure 1F](#fig1){ref-type="fig"}). In addition, analysis of dependencies of the lesions supports *SPOP* mutations preceding *CHD1* deletions; no lesions were predicted to precede *SPOP* mutation ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). Together, these data nominate a distinct prostate cancer class characterized by early *SPOP* mutations and genomic instability. We posited that the *SPOP* mutation impacts genome maintenance and prioritized *SPOP* for functional studies.

We explored the functional role of SPOP in vivo, using zebrafish as a rapidly assessable vertebrate model system. SPOP is highly conserved (97.3% identical at the amino acid level between human and zebrafish, [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Knockdown of *Spop* by two different splice-blocking morpholinos (MO5, MO7) dramatically impaired brain and eye development as well as decreased overall body size ([Figure 2A,B](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}), resulted in gene expression changes consistent with p53 activation, and apoptosis measured by TUNEL assay ([Figure 2C](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}). Microinjection of human SPOP mRNA rescued these phenotypes, confirming specificity of the morpholino effects ([Figure 2A--C](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}). To nominate signaling pathways impacted by Spop, we performed transcriptional profiling using RNA-seq on zebrafish with *Spop* knockdown and ectopic expression of wild-type SPOP (SPOP-wt) and SPOP-F133V, the most commonly mutated residue in prostate cancer ([Figure 2D](#fig2){ref-type="fig"}). Consistent with recently reported proteomic data ([@bib31]) and heterodimerization between mutant and wild-type SPOP in our models ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}), transcriptional responses to SPOP-F133V compared with SPOP-wt and Spop morpholino showed a pattern consistent with dominant negative, selective loss of function; SPOP-F133V correlated with SPOP-wt for some gene sets (Cluster B) and correlated with Spop morpholino for others (Cluster A) ([Figure 2D](#fig2){ref-type="fig"}, [Figure 2---source data 1](#SD1-data){ref-type="supplementary-material"}). Gene set enrichment analyses (GSEA) revealed gene sets involving DNA repair impacted by modulating SPOP function ([Figure 2---source data 2](#SD2-data){ref-type="supplementary-material"}). Notably, the transcriptional response to F133V correlated highly with BRCA1 inactivation ([Figure 2E](#fig2){ref-type="fig"}). While SPOP has been previously proposed as involved in DNA damage and repair (DDR) signaling based on in vitro experiments ([@bib35]), these results for the first time implicate a functional role for SPOP in DDR signaling in vivo and suggest this function is selectively impaired by prostate cancer-derived SPOP mutations. To test this hypothesis in human prostate cancers, we performed unsupervised hierarchical clustering of transcriptional data from 11 SPOP mutant and 53 SPOP wild-type tumors, based on the transcriptional signature of BRCA1 inactivation (MSigDB: M2748). We observed significant segregation of SPOP mutant tumors (p-value = 9.5e^−07^, [Figure 2F](#fig2){ref-type="fig"}) using this signature, with less robust segregation of tumors harboring CHD1 or MAP3K7 deletions co-occurring with SPOP mutation ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). These data suggest that human prostate cancers with *SPOP* mutations show transcriptional effects similar to BRCA1 inactivation, consistent with a role for SPOP in DSB repair. Supporting this hypothesis, we observed a trend of mutual exclusivity between *SPOP* mutations and *BRCA1* alterations in genomic data (p-value = 0.0496, [Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}).10.7554/eLife.09207.009Figure 2.SPOP mediates DNA damage repair.(**A**) Evaluation of SPOP function during zebrafish development. Phenotype of morpholino-mediated *Spop* knockdown (MO5) in zebrafish embryos at 70 hr post fertilization (hpf). Injection of human SPOP mRNA (250 pg) rescued the phenotype. (**B**) Quantification of the rescue of SPOP phenotype after ectopic expression of human SPOP mRNA. Results are represented as s.e.m. (**C**) Whole mount TUNEL assay to determine apoptosis in zebrafish embryos. Arrows point to apoptotic cells (brown). Shown are representative images. (**D**) Heatmap representation of gene expression differences in zebrafish embryos ectopically expressing SPOP-wt or SPOP-F133V compared to SPOP knockdown by morpholino (MO). The list of genes can be found in [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}. Number of genes per block: A (198), B (429), C (223). (**E**) Gene set enrichment analysis (GSEA) of RNA sequencing data derived from zebrafish embryos expressing SPOP-wt or SPOP-F133V (24 hpf). Enrichment plot for the BRCA1 gene signature is shown. Molecular Signatures Database (MSigDB) systematic name indicated in brackets. (NES) Normalized Enrichment Score. (FDR) False Discovery Rate. (**F**) Dendrogram of human primary prostate cancer cases based on BRCA1 knockdown genes (MSigDB: M2748). Unsupervised clustering of RNA-seq data from human primary prostate cancer with wild-type (n = 53) or mutant SPOP (n = 11), performed on the BRCA1 knockdown gene signature (M2748) identified in zebrafish embryos by GSEA as shown in (**E**).**DOI:** [http://dx.doi.org/10.7554/eLife.09207.009](10.7554/eLife.09207.009)10.7554/eLife.09207.010Figure 2---source data 1.List of genes contained in blocks A, B, and C in the heatmap in [Figure 2D](#fig2){ref-type="fig"}.Provided as excel file.**DOI:** [http://dx.doi.org/10.7554/eLife.09207.010](10.7554/eLife.09207.010)10.7554/eLife.09207.011Figure 2---source data 2.Results from GSEA comparing zebrafish embryos ectopically expressing SPOP-wt or -F133V.Provided as excel file.**DOI:** [http://dx.doi.org/10.7554/eLife.09207.011](10.7554/eLife.09207.011)10.7554/eLife.09207.012Figure 2---figure supplement 1.*Spop* knockdown in zebrafish using morpholinos results in a developmental phenotype.(**A**) Multiple protein sequence alignment of SPOP from Homo sapiens and zebrafish (*Danio rerio*) reveals 97.3% identity between humans and zebrafish on the amino acid level. (**B**) Schematic representation of zebrafish SPOP mRNA. Colored boxes indicate exons. MO5 and MO7 indicate the targeted sites of the SPOP-specific morpholinos. F1 and R5 indicate the sites were the primers bind, which were used to amplify exons 1--5 for molecular validation of morpholino efficiency. (**C**) Image of an agarose gel used to analyze zebrafish SPOP splice variants after morpholino treatment. (**D**) Propidium iodide-based cell cycle analyses of cells from zebrafish embryos (24 hr) treated with or without SPOP-specific morpholino. (**E**) Quantification of TUNEL-positive cells in the midbrain area of zebrafish embryos (24 hpf) treated with SPOP morpholino or in combination with WT-SPOP mRNA as shown in [Figure 2C](#fig2){ref-type="fig"}. (**F**) Example of zebrafish embryos (48 hpf) injected with a second splice-blocking morpholino (MO7). Rescue of the effects of MO7 on zebrafish development by coinjecting WT-SPOP mRNA. (**G**) qPCR-based validation of differentially expressed transcripts identified by RNA-seq.**DOI:** [http://dx.doi.org/10.7554/eLife.09207.012](10.7554/eLife.09207.012)10.7554/eLife.09207.013Figure 2---figure supplement 2.SPOP wt and F133V form heterodimers.(**A**) 22Rv1 cells transfected with SPOP wt and F133V constructs tagged with HA or myc underwent immunoprecipitation (IP) with anti-HA antibody followed by immunoblot for HA and myc. (**B**) Mouse prostate cells with Cre-inducible SPOP-F133V with a FLAG tag underwent immunoprecipitation (IP) with anti-FLAG antibody followed by immunoblot for SPOP. Upper band is flag-tagged mutant SPOP; lower band is endogenous SPOP.**DOI:** [http://dx.doi.org/10.7554/eLife.09207.013](10.7554/eLife.09207.013)10.7554/eLife.09207.014Figure 2---figure supplement 3.Dendrogram of human primary prostate cancer cases based on BRCA1 knockdown genes (MSigDB: M2748).Unsupervised clustering of RNA-seq data from human primary prostate cancer annotated for status of *SPOP* mutation, *CHD1* deletion, and *MAP3K7* deletion, performed on the BRCA-1 knockdown gene signature (M2748).**DOI:** [http://dx.doi.org/10.7554/eLife.09207.014](10.7554/eLife.09207.014)10.7554/eLife.09207.015Figure 2---figure supplement 4.*SPOP* mutation and alterations in DNA repair genes in prostate cancer.(**A**) *SPOP* mutation and somatic *BRCA1* gene alterations are mutually exclusive in primary prostate cancer. The cBio portal oncoprint tool was used to graphically summarize the mutations in *SPOP* and genomic deletions and mutations in *BRCA1* in 402 human prostate cancer samples. Samples with no alterations are not displayed. *SPOP* mutations and *BRCA1* alterations are mutually exclusive (one-tail Fisher\'s test, p-value = 0.0496). (**B**) *SPOP* mutation and DNA repair pathway alterations in castration-resistant prostate cancer. The cBio portal oncoprint tool was used to graphically summarize the mutations in *SPOP* and mutations in *BRCA2 and ATM* in 150 metatstaic castration-resistant prostate cancer samples.**DOI:** [http://dx.doi.org/10.7554/eLife.09207.015](10.7554/eLife.09207.015)

Consistent with the hypothesis that SPOP is involved in DSB repair in prostate cells, SPOP forms nuclear foci in prostate cells after γ-irradiation ([Figure 3A](#fig3){ref-type="fig"}) and stable expression of SPOP-wt conferred resistance to DSB-inducing agents cisplatin and camptothecin (CPT) ([Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). To further define the impact of SPOP mutation in response to DNA damage, we utilized primary prostate cells isolated from transgenic mice with Cre-dependent conditional expression of SPOP-F133V. After transduction with Tamoxifen-inducible Cre (Cre-ERT2), cells were treated with 4-OH tamoxifen or vehicle and exposed to ionizing radiation (IR) ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Spop localized in nuclear foci similar to human LNCaP cells in mouse prostate cells (MPCs) after IR, with no alteration in foci by expression of SPOP-F133V ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1I](#fig3s1){ref-type="fig"}). Induction of SPOP-F133V resulted in delayed recovery from IR-induced damage as measured by comet assay ([Figure 3B](#fig3){ref-type="fig"}). No differences were seen in apoptosis after IR, as measured by PARP cleavage ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}), subG1 events, or caspase-3 cleavage (data not shown). To functionally characterize how SPOP mutations affect response to DSB, we expressed SPOP-wt and SPOP-F133V in benign prostate epithelial cells (RWPE) and prostate cancer cells (22Rv1), and examined the induction, recognition, and resolution of CPT-induced DSBs. We found that DSB formation (measured by γH2AX foci and protein levels) was not affected by modulating SPOP function with siRNA, or expression of wildtype or mutant SPOP ([Figure 3C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1C,D](#fig3s1){ref-type="fig"}). Furthermore, there were no observed differences in early DNA damage signaling events, such as phosphorylation of ATM, ATR, Chk1, and Chk2 ([Figure 3---figure supplement 1E--H](#fig3s1){ref-type="fig"}), indicating that SPOP did not affect initial induction and recognition of DSBs or initial steps in DDR signaling. Consistent with this, SPOP showed only limited co-localization with early markers of DSB (γH2AX, phospho-ATM) in irradiated prostate cells ([Figure 3---figure supplement 1I](#fig3s1){ref-type="fig"}).10.7554/eLife.09207.016Figure 3.SPOP mutation impairs HDR and promotes NHEJ and SPOP-wt modulates DSB repair activity similar to BRCA1.(**A**) SPOP forms nuclear foci after induction of DNA damage by γ-irradiation (3GY) in prostate cells derived from transgenic mice (MPC) and human LNCaP cells. Red represents nuclear Spop protein foci. Blue represents nuclear DNA stained with DAPI. (**B**) MPC expressing Cre-inducible SPOP-F133V was infected with tamoxifen-inducible Cre (CreERT2), and DNA damage was assessed after IR with comet assays. Inset: representative cells showing comet tails after IR. (**C**, **D**, **E**) Quantification of γH2AX, 53BP1, or RAD51 foci in RWPE cells overexpressing WT or F133V mutant SPOP after camptothecin (CPT) (1 μM) induced DNA damage. Time indicates the observation interval in minutes including double strand break (DSB) induction (0--60 min) and recovery (60--180 min). Shown are the percentages of cells for each genotype with more than 5 foci per nucleus. Results are represented as s.e.m. (**F**) Representative pictures showing γH2AX, RAD51, or 53BP1 foci (red or green). Blue represents nuclear DNA stained with DAPI. (**G**) Quantification of Rad51 foci in γ-irradiated (2GY) MPC with tamoxifen-inducible SPOP-F133V. Rad51 foci were counted 30 min post irradiation. (**H**) Representative pictures showing Rad51 foci in mouse prostate epithelial cells before and after γ-irradiation (2GY). (**I**) Quantification of RAD51 foci in RWPE cells treated with siSPOP or control siRNA and subsequently exposed to CPT (1 μM, 1 hr).**DOI:** [http://dx.doi.org/10.7554/eLife.09207.016](10.7554/eLife.09207.016)10.7554/eLife.09207.017Figure 3---figure supplement 1.SPOP and response to DSB.(**A**, **B**) Clonogenic assay measuring survival of stable SPOP-expressing 22Rv1 cells after CPT or cisplatin treatment. (**C**) Western blot for the DSB marker γH2AX using protein lysates from RWPE cells before and after CPT treatment (30 min) in RWPE cells either ectopically expressing SPOP-wt or -F133V or (**D**) treated with control (sicon) or SPOP targeting siRNA (siSPOP). (**E**--**H**) Western blot for DNA damage signaling proteins using protein lysates from 22Rv1 (**E**, **F**) or RWPE (**G**, **H**) cells before and after CPT treatment (30 min). Cells either ectopically expressed SPOP-wt or SPOP-F133V or were treated with control (sicon) or SPOP-targeting siRNA (siSPOP). (**I**) Immunofluorescence-based partial colocalization of SPOP (red) and early DNA damage markers gH2AX or pATM (green). MPC-expressing Cre-inducible SPOP-F133V was transduced with tamoxifen-inducible Cre (CreERT2). MPC were treated with 4-OH tamoxifen or vehicle and exposed to ionizing radiation (3GY).**DOI:** [http://dx.doi.org/10.7554/eLife.09207.017](10.7554/eLife.09207.017)10.7554/eLife.09207.018Figure 3---figure supplement 2.Prostate cells derived from transgenic mice (MPC) expressing Cre-inducible SPOP-F133V were infected with tamoxifen-inducible Cre (CreERT2) and treated with 4-OH tamoxifen (+Tam) or vehicle (−Tam) and exposed to 15 GY IR followed by Immunoblot for SPOP, PARP, and vinculin (loading control) blot after 3 hr recovery.**DOI:** [http://dx.doi.org/10.7554/eLife.09207.018](10.7554/eLife.09207.018)10.7554/eLife.09207.019Figure 3---figure supplement 3.SPOP mutation impairs HDR-DSB repair and promotes NHEJ.**(A-F)** Quantification of 53BP1 and RAD51 foci in 22RV1 and RWPE cells ectopically expressing SPOP-wt or SPOP-F133V after camptothecin (CPT) (1 μM) or gamma irradiation (3GY)-induced DNA damage. Time indicates the observation interval in minutes including DSB induction (0--60 min) and recovery (60--1440 min). Shown are the percentages of cells for each genotype with more than 5 foci per nucleus. (**G**, **H**) Representative pictures of 53BP1 or RAD51 foci (green). Blue represents nuclear DNA stained with DAPI. (**I**) Quantification of 53BP1 foci in RWPE ectopically expressing SPOP-wt, SPOP-F102C or SPOP-F133V mutant SPOP after CPT (1 μM, 1 hr)-induced DNA damage. (**J**) Immunofluorescence staining of MYC-tagged SPOP in RWPE cells confirms nuclear localization. Blue indicates DAPI-stained DNA. Green foci indicate SPOP protein. Error bars represent s.e.m. (**K**) Propidium iodide-based cell cycle analyses of RWPE cells.**DOI:** [http://dx.doi.org/10.7554/eLife.09207.019](10.7554/eLife.09207.019)

We next examined specific markers (53BP1, RAD51) of the two major DSB repair pathways, HDR and NHEJ. RAD51 is a component of the HDR pathway and a marker for engagement of the HDR machinery ([@bib5]). 53BP1 is a positive regulator of NHEJ that blocks 5′-DNA-end resection and therefore functions at the intersection of HDR and NHEJ; if 53BP1 is not cleared from sites of DSB by HDR components, it promotes error prone NHEJ ([@bib24]). Strikingly, SPOP-F133V-expressing prostate cells showed delayed clearance of 53BP1 from sites of DSB ([Figure 3D,F](#fig3){ref-type="fig"}, [Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}); similar effects were seen with another SPOP mutation (F102C) commonly observed in prostate cancer ([Figure 3---figure supplement 3I,J](#fig3s3){ref-type="fig"}). Furthermore, SPOP-wt increased RAD51 foci formation compared to controls, while SPOP-F133V-expressing cells showed a dramatic decrease in RAD51 foci formation ([Figure 3E,F](#fig3){ref-type="fig"}, [Figure 3---figure supplement 3B](#fig3s3){ref-type="fig"}), consistent with impairment of HDR. Induction of SPOP-F133V in primary MPCs similarly decreased Rad51 foci after IR ([Figure 3G,H](#fig3){ref-type="fig"}). Knockdown of *SPOP* also resulted in a decrease of RAD51 foci, suggesting a selective loss of function of SPOP-F133V in HDR ([Figure 3I](#fig3){ref-type="fig"}). We also observed decreased clearance of 53BP1 foci and decreased RAD51 foci formation in SPOP-F133V-expressing cells after gamma irradiation, indicating that this effect is not specific to one mechanism of DSB induction ([Figure 3---figure supplement 3C--H](#fig3s3){ref-type="fig"}). The observed changes in DSB repair were not accompanied by changes in the cell cycle distribution of cells expressing SPOP-wt or F133V under these conditions ([Figure 3---figure supplement 3K](#fig3s3){ref-type="fig"}).

We next investigated the role of SPOP in DSB repair using the well established DR-GFP and Pem1-Ad2-EGFP reporter assays as functional readouts for HDR and NHEJ, respectively ([Figure 4A,D](#fig4){ref-type="fig"}) ([@bib25]; [@bib29]). In the DR-GFP assay, knockdown of *SPOP* by siRNA decreased HDR competence in human epithelial cells to a similar level of *BRCA1* knockdown ([Figure 4B](#fig4){ref-type="fig"}). Conversely, ectopically expressed SPOP-wt increased the HDR competence in these cells, with partial loss of this function by mutant SPOP ([Figure 4C](#fig4){ref-type="fig"}). In contrast, the Pem1-Ad2-EGFP NHEJ reporter assay indicated an increase of NHEJ activity in SPOP-F133V expressing epithelial cells, while both *SPOP* siRNA and *BRCA1* siRNA increased NHEJ ([Figure 4E,F](#fig4){ref-type="fig"}). Taken together, these results suggest that SPOP promotes HDR, while somatic mutation in *SPOP*, as observed in prostate cancer with increased genomic rearrangements, impairs HDR and promotes error-prone NHEJ.10.7554/eLife.09207.020Figure 4.SPOP modulates DSB repair activity similar to BRCA1.(**A**) Schematic overview of the DR-GFP assay used to measure homology-directed repair (HDR) activity. (**B**, **C**) Analysis of the HDR-activity in HEK 293 cells with siRNA knockdown of SPOP or BRCA1 and ectopically expressing SPOP-wt or SPOP-F133V. (**D**) Schematic overview of the Pem1-Ad2-EGFP assay used to measure NHEJ-activity. (**E**, **F**) Analysis of the NHEJ-activity in HEK 293 cells with siRNA knockdown of SPOP or BRCA1 and ectopically expressing SPOP-wt or SPOP-F133V. All results are represented as s.e.m.**DOI:** [http://dx.doi.org/10.7554/eLife.09207.020](10.7554/eLife.09207.020)

Human cancers with underlying defects in HDR (such as *BRCA1* inactivated breast and ovarian cancers) ([@bib8]; [@bib13]; [@bib2]; [@bib33]) show sensitivity to poly (ADP-ribose) polymerase 1 (PARP) inhibition. To test if SPOP inactivation conferred sensitivity to PARP inhibition after DSB induction, we utilized siRNA targeting SPOP in human prostate cancer cell lines (PC-3, LnCap, 22Rv1), followed by irradiation (5GY) and incubation with the PARP inhibitors olaparib or veliparib. Reduction of SPOP expression increased the sensitivity of these prostate cancer cells to both PARP inhibitors ([Figure 5A--C](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1B,C](#fig5s1){ref-type="fig"}). To test if SPOP mutation also sensitizes to PARP inhibition, we treated MPCs (control vs tamoxifen-induced SPOP-F133V) with olaparib followed by IR---expression of SPOP-F133V increased sensitivity to olaparib similar to loss of SPOP in human prostate cancer cell lines ([Figure 5D](#fig5){ref-type="fig"}). This was further confirmed in 22Rv1 cells ectopically expressing SPOP-F133V, which also showed an increased sensitivity to olaparib in viability assays, while cells ectopically expressing SPOP-wt were relatively resistant ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). We further confirmed these results in HEK293 cells stably overexpressing the two common SPOP mutants (Y87N, F133V) in clonogenic survival assays ([Figure 5E,F](#fig5){ref-type="fig"}).10.7554/eLife.09207.021Figure 5.SPOP mutation sensitizes cells to therapeutic PARP inhibition.(**A**--**D**) Analysis of sensitivity to the PARP inhibitor olaparib in irradiated (5GY) prostate cancer (PC-3, LNCaP, 22Rv1) and mouse prostate epithelial cells (MPC) after *SPOP* knockdown (siSPOP) or tamoxifen-inducible SPOP^F133V^ expression. *BRCA1* knockdown (siBRCA1) and non-targeting siRNA (sictrl) served as positive or negative control. The IC50 of olaparib for each genotype is indicated in Molar (M). (**E**) Analysis of the sensitivity of most frequently occurring prostate-specific SPOP mutants Y87N and F133V to olaparib in clonogenic assays using HEK293 cells. (**F**) Representative examples from the clonogenic assay used to assess long-term survival in HEK293 cells stably expressing SPOP-wt or SPOP mutants. (**G**) Impact of SPOP mutation on induction of genomic instability in 22Rv1 cells after olaparib (1 μM) treatment as measured by comet assay. Increased genomic instability was measured by an increase in the tail moment. (**H**) Genomic instability in tamoxifen-inducible SPOP-F133V expressing mouse prostate cells after γ-irradiation (15GY) with and without olaparib (1 μM) treatment as measured by comet assay. All results are represented as s.e.m.**DOI:** [http://dx.doi.org/10.7554/eLife.09207.021](10.7554/eLife.09207.021)10.7554/eLife.09207.022Figure 5---figure supplement 1.SPOP mutation and loss sensitize prostate cancer cells to therapeutic PARP inhibition.(**A**) In vitro drug sensitivity assay of 22Rv1 cells expressing SPOP-wt or SPOP-F133V. Cells were treated with the indicated concentrations of olaparib for 96 hr. LacZ was used as empty control expression vector. (**B**, **C**) In vitro drug sensitivity assay of 22Rv1 and PC-3 cells treated with control siRNA (sictrl), SPOP, or BRCA1 targeting siRNA (siSPOP, siBRCA1). After irradiation (5GY) cells were treated with the PARP-1 inhibitor veliparib for 96 hr. IC50 values for each genotype are indicated in Molar (M).**DOI:** [http://dx.doi.org/10.7554/eLife.09207.022](10.7554/eLife.09207.022)

To determine if the altered sensitivity to PARP inhibitors was associated with increased DNA damage, consistent with impaired double-strand break repair, we performed single-cell gel electrophoresis (comet assay) in prostate cells treated with olaparib. The comet assay revealed an increase of genomic instability in SPOP-F133V RWPE cells after PARP inhibition, similar to *SPOP* (and *BRCA1*) knockdown with siRNA ([Figure 5G](#fig5){ref-type="fig"}). Similarly, primary MPCs expressing SPOP-F133V showed increased damage after olaparib treatment ([Figure 5H](#fig5){ref-type="fig"}). Taken together, these data argue that SPOP mutation confers sensitivity to PARP inhibition due to impaired error-free HDR DSB repair and an increase in error-prone NHEJ.

Discussion {#s3}
==========

In summary, here we report that SPOP, the substrate recognition component of an E3 ubiquitin ligase, is a regulator of the HDR-based DSB repair machinery. Using functional genetic approaches, we find that prostate-specific SPOP mutants deregulate DSB repair by promoting the error-prone NHEJ pathway ([Figure 6](#fig6){ref-type="fig"}). Importantly, after DSB induction, this loss of function leads to an increased sensitivity of mutant SPOP prostate cancer cells to PARP inhibition. These observations provide the first mechanism for the increased genomic instability of SPOP mutant prostate cancer, but also suggest that similar to other cancers with impaired HDR, this distinct class of cancer might benefit from treatment with clinically established DNA damaging therapeutics. This study therefore provides a rationale for hypothesis-based biomarker-driven clinical trials using PARP inhibitors or other DNA damaging agents in patients with prostate cancer.10.7554/eLife.09207.023Figure 6.Proposed model of the effects of SPOP mutation on genome instability.In prostate epithelial cells, SPOP-wt promotes error-free HR and maintains genome stability. SPOP mutation impairs HR repair and promotes error-prone NHEJ, leading to increased genomic instability.**DOI:** [http://dx.doi.org/10.7554/eLife.09207.023](10.7554/eLife.09207.023)

Genomic rearrangements represent critical events deregulating prostate cancer genomes and driving tumorigenesis, although among individual cancer samples, there is marked variability in number and character of structural rearrangements. Here, we identified a genomically unstable subclass of primary prostate cancer characterized by dramatically increased intrachromosomal rearrangements. This subset of clinically localized, treatment-naive prostate cancers display a degree of genomic instability previously thought only to occur in late stage, metastatic tumors. Importantly, increased rearrangements likely result in higher total SCNA burden, which is associated with more aggressive clinical behavior ([@bib19]; [@bib21]).

Increased rearrangements were associated with mutations in *SPOP*, encoding the substrate-recognition component of an E3 ubiquitin ligase complex. *SPOP* mutations are the most common point mutations in prostate cancer, but their role in promoting prostate cancer pathogenesis remains unclear. SPOP mutations occur early in the history of prostate cancer, based on clonality analysis reported here and presence in the prostate cancer precursor high grade prostatic intraepithelial neoplasia (HG-PIN) ([@bib4]), potentially consistent with a 'gatekeeper' role in genome maintenance.

Consistent with increased intrachromosomal rearrangements in *SPOP* mutant cancers, in vivo data nominated a functional role for SPOP in DSB repair, similar to BRCA1. Interestingly, *SPOP* loss of function induced a developmental phenotype of neuronal degeneration and apoptosis; similar effects have been reported with other genes modulating DNA repair, including *BRCA1* ([@bib27]).

*SPOP* encodes the substrate recognition component of an E3 ubiquitin ligase, and here we identified a role for SPOP in regulating the HDR-based DSB repair machinery. Notably, many established components of the DNA damage response are components of enzymes regulating ubiquitylation ([@bib9]). A number of substrates have been reported as deregulated by prostate cancer-derived SPOP mutations, but the relevance of these in vitro findings to human prostate cancers is still unclear ([@bib16], [@bib17]; [@bib1]; [@bib31]; [@bib36]). In contrast, we focused on the phenotypes observed in human prostate cancers harboring *SPOP* mutations. Using functional genetic approaches, we find that prostate-specific SPOP mutants deregulate DSB repair by promoting the error-prone NHEJ pathway ([Figure 4F](#fig4){ref-type="fig"}).

The clinical importance of our findings is timely as potent PARP inhibitors, inducing synthetic lethality in cancers with alterations in DSB repair, are being evaluated and utilized in human cancers ([@bib14]; [@bib33]; [@bib28]). Here, we define a novel biomarker for increased genomic instability in clinically localized prostate cancer, provide the first mechanism by which SPOP mutations induce these alterations, and also suggest that similar to other cancers with impaired HDR, this distinct class of cancer may benefit from treatment with clinically established DNA damaging therapeutics, providing a rationale for genotype-based clinical trials.

Materials and methods {#s4}
=====================

Human cell lines {#s4-1}
----------------

Cells were purchased from ATCC and cultured according to the manufacturer\'s instructions. All cells were maintained with 1% penicillin/streptomycin (15140-122, Gibco, Grand Island, NY, United States). Cells were treated with camptothecin (C9911, Sigma-Aldrich, St. Louis, MO, United States), olaparib (AstraZeneca, United Kingdom), veliparib (Selleckchem, United Kingdom), or cisplatin (Sigma-Aldrich) at the indicated concentrations. For SPOP expression, lentiviral vectors (pLenti6/V5-Dest Gateway vector, V496-10, Invitrogen, Grand Island, NY, United States) coding for mutant or wild-type SPOP were used. Viruses were titrated to equalize infectivity and protein expression. Viral titers were measured by a p24 ELISA (Lenti-X p24 rapid titer kit, PT5002-2, Clontech, Mountain View, CA, United States). Viral transduction was performed by using Polybrene transfection reagent (TR-1003-G, Millipore, Billerica, MA, United States) at a final concentration of 8 ng/μl. Stable cell lines for WT or mutant SPOP were generated by pLenti viral transduction and subsequent selection by cell sorting for RFP using an Aria-II cell sorter (BD Biosciences, San Jose, CA, United States). Stable selection was monitored over time by confirming RFP- and MYC-tagged SPOP expression.

Primary mouse prostate cells from conditional SPOP-F133V transgenic mice {#s4-2}
------------------------------------------------------------------------

### Gene targeting {#s4-2-1}

All mouse studies were approved by the WCMC IACUC under protocol 2012-0065. To generate mice conditionally expressing flag-myc tagged human *SPOP*^*F133V*^ pBTGinv (kind gift from Dr Yu Chen) was used to clone the cDNA subsequently to two inverted loxP sites, as previously described by [@bib10]. This vector, pBigT-invloxP-SPOP^F133V^-IRES-nlsEFP was cloned into Rosa26-Pam1 (Addgene 15036). Vector was targeted into ES cells derived from albino C57B6 mice and injected into C57B6 blastocysts. Cre induction of SPOP-F133V was confirmed in ES cells. *R26*^*F133V/+*^ mice were generated and confirmed though standard genotyping.

### Primary mouse prostate cell isolation {#s4-2-2}

Murine prostates were isolated from 10-week-old *R26*^*F133V/+*^ mice and primary MPC lines were generated as described by [@bib23]. Digested tissue was immediately mixed with growth factor reduced matrigel, plated in 36 drops and covered with organoid media as described by [@bib20], for 3--4 days. After 3--4 day of 3D culture cells were plated onto collagen-coated plates and grown as 2D cultures.

### Cre-induction and sorting {#s4-2-3}

Stable MPC cells were transduced with a retrovirus expressing Cre-ERT2 (kind gift from Yu Chen) followed by puromycin selection. Following 48-hr treatment of the MPC cells with 1 μM 4-hydroxytamoxifen (Sigma-Aldrich) or vehicle, cells were sorted for GFP positivity using FACSAria II cell sorter (BD Biosciences). Vehicle-treated cells were sorted through a similar process.

siRNA transfection {#s4-3}
------------------

Reagents for siRNA knockdown of SPOP and BRCA1 were purchased from Dharmacon (Lafayette, CO, United States). The siGenome smartpools were used to target SPOP (M-017919-02-0005), BRCA1 (M-003461-02-0005) as well as non-targeting control (D-001206-13-05). The siRNA oligonucleotides were transfected with Lipofectamine 2000 at a final concentration of 50--100 pmol and incubated for 48 hr.

### Immunofluorescence {#s4-3-1}

Cells were cultured on gelatin (0.1%) coated coverslips in 12-well plates, treated with CPT (1 μM, 1 hr) and then recovered for 2 hr in medium without CPT. Cells were collected at indicated time points and fixed in 4% PFA for 20 min, permeabilized in PBS with 0.5% Triton X 100 (EMD, TX1568-1) and blocked in 1% BSA in 1× PBS (P0195, Teknova, Hollister, CA, United States) for 30 min. Human prostate cells were then incubated in anti-Phospho (Ser139) H2AX (NBP1-64745, 1:500, Novus Biologicals, Littleton, CO, United States), anti-MYC-tag (clone 4A6, Millipore, 1:300), anti-RAD51 (PC130, 1:500, Calbiochem, United Kingdom), or anti-53BP1 (NB 100-904, Novus Biologicals, 1:500) primary antibodies followed by Alexa Fluor 555 or Alexa Fluor 488 labeled anti-mouse or anti-rabbit secondary antibodies (1:500) (A-21422, A-1101, Life Technologies). Mouse prostate epithelial cells were incubated in anti-phospho ATM (ab36810, 1:500, Abcam, United Kingdom), anti-Rad51 (Abcam, ab88572, 1:100), anti-γH2AX (Abcam, ab26350, 1:1000), and anti-SPOP (developed in the Rubin lab, 1:300). Pictures were taken on a Zeiss LSM 510 Laser Scanning Confocal Microscope.

### Immunoblot analysis {#s4-3-2}

Cells were lysed as previously described ([@bib4]). Proteins were quantified by BCA protein assay kit (23227, Thermo Scientific). 25--50 μg of total proteins were loaded onto a 4--15% gradient SDS-PAGE (Mini Protean TGX, 456-1084, Bio-Rad, Hercules, CA, United States) and subsequently transferred to PVDF membranes (Bio-Rad). Membranes were incubated with the following primary antibodies at the indicated dilutions: anti-SPOP rabbit monoclonal antibody (Epitomics), anti-MYC-tag (for SPOP) (Millipore, cat.no. 05-724, 1:1000), anti-phospho H2AX (pSer139) (NBP1-64745, Novus Biologicals, 1:1000), anti-total H2AX (NBP1-61896, Novus Biologicals, 1:1000), anti-RAD51 (ab133534, abcam, 1:1000), anti-BRCA1 (ab131360, abcam, 1:1000), anti-CHK1 (2G1D5, 1:1000, Cell Signaling, Danvers, MA, United States), anti phospho CHK1 (2348, Cell Signaling, 1:1000), anti-CHK2 (2662, Cell Signaling, 1:1000), anti-phospho CHK2 (2661, Cell Signaling, 1:1000), anti-ATR (Cell Signaling, 1:1000), anti-phospho ATR (2853, Cell Signaling, 1:1000), anti ATM (07-1286, Millipore, 1:1000), anti-phospho ATM (5883, Cell Signaling, 1:1000), anti-GAPDH (AB2302, Millipore, 1:5000). Primary antibodies were detected with HRP-conjugated anti-rabbit (32260, 1:10.000, Grand Island, NY, United States), anti-mouse (32230, Pierce, 1:10.000), anti-chicken (31401, Pierce, 1:5000) or HRP-conjugated streptavidin (18-152, Millipore, 1:5000).

In vitro drug sensitivity assay {#s4-4}
-------------------------------

Human prostate and mouse prostate--epithelial cells (1000--5000) were seeded into 96-well microtiter plates (CLS3610-48EA, Sigma Aldrich). After irradiation (5GY) cells were treated with olaparib or veliparib in a concentration range of 0.0001 μM--100 μM for 72--96 hr. DMSO was used as control. Cell viability was measured by using the CyQuant NF cell proliferation assay (Life Technologies, [C35006](http://www.thermofisher.com/order/catalog/product/C35006)) according to the manufacturer\'s instructions. Data normalization and nonlinear regression to calculate IC50 values was performed with Graph Pad Prism.

### Clonogenic survival assays {#s4-4-1}

Stable SPOP-expressing HEK293 or 22Rv1 cells were treated with cisplatin (24 hr, concentration as indicated) or olaparib (1 μM, 4 days). 50 cells were seeded per well of a 12-well plate, grown for 10--12 days, fixed and stained with ethanol (10%) and crystal violet (0.09%). Colonies containing 50 cells or more were counted, and the drug cytotoxicity was calculated as the ratio of colonies formed after drug treatment relative to colonies from untreated cells.

### Single-cell gel electrophoresis {#s4-4-2}

Single-cell gel electrophoresis (comet assay) was performed according to the manufacturer\'s instructions (Trevigen, Gaithersburg, MD, United States). 10^5^ cells/ml were mixed with molten LM agarose in a ratio of 1:10 and spread on a comet slide. Cells were subsequently lysed and subjected to electrophoresis. Cells were fixed and stained with SYBR Green. Images were collected with a 20× objective lens using a monochrome camera (CV-M4+CL, Jai, Japan) fitted in an Olympus BX51 microscope (Olympus, Center Valley, PA, United States). COMETscore v1.5 was used for image analysis, and 50--100 individual cells were analyzed per condition. The results are shown as comet tail moments, which is a representation of the fluorescence intensity in the tail relative to the head.

### DR-GFP (HDR) and Pem1-Ad2-EGFP (NHEJ) reporter assay {#s4-4-3}

Cells were electroporated using the cell line nucleofactor kit V (VCA-1003, Lonza, Allendale, NJ, United States) with positive control plasmids (pNZE) and combinations of HDR-(pDRGFP) or NHEJ-(pPEM1-Ad2-EGFP) reporter constructs and an expression vector for the restriction enzyme I-SceI as described previously ([@bib25]). All the plasmids used in the GFP-reporter assay were a kind gift of Maria Jasin, Memorial Sloan Kettering Cancer Center, New York. The GFP expression induced by the positive control plasmid was used to normalize the electroporation efficiency. Negative controls contained the reporter construct and empty expression vectors lacking I-SceI. Cells were grown for 48 hr and processed for further flow cytometry analysis.

### Flow cytometry {#s4-4-4}

Cells were fixed in PFA (2% vol/vol in PBS), permeabilized in 0.5% Triton X 100, and blocked in 1% BSA. Cells were incubated overnight in mouse Alexa Fluor 647 labeled anti-MYC-Tag antibodies (clone 9B11, cat.no: 2233, Cell Signaling, 1:50). SPOP (MYC-tag) and GFP expression was quantified by the LSRII flow cytometer (BD Biosciences).

### Cell cycle analysis {#s4-4-5}

RWPE cells were transduced with LacZ, WT SPOP, or F133V SPOP lentiviral particles. Transduced cells were treated with Nocodazole (40 ng/ml) for 18 hr to synchronize cell cycle. Cell cycle distribution was determined by FACS 24 hr after culturing synchronized cells in normal growth media and labeling cells with propidium iodide (PI).

### Zebrafish {#s4-4-6}

Wild-type zebrafish (strain AB/T) were maintained as described previously ([@bib9]). For functional studies, embryos were harvested at the one cell stage and yolk injected with SPOP-targeting morpholino (final 2--4 ng) or SPOP mRNA at the indicated concentrations. For phenotypical analysis, embryos were monitored for 5 days. RNA was isolated using Trizol reagent (15596-026, Life Technologies) at 24 hpf for RNA sequencing after dechorionating the embryos with pronase. For cell cycle analysis, embryos were homogenized and individual cells were stained with propidium iodide. All protocols were performed with prior approval of the WCMC IACUC (2011-0026).

### Zebrafish whole mount apoptosis assay {#s4-4-7}

Embryos (24 hpf) were fixed in 4% PFA overnight. Embryos were than washed in PBS Tween (PBT) and Methanol, rehydrated in a series of Methanol-PBT dilutions (75% MeOH/25% PBT, 50% MeOH/50% PBT, 25% MeOH/75% PBT), and washed three times in PBT. Afterwards embryos were digested with PK (5 min, 10 μg/ml). PK digestion was followed by two PBT washes, a refixation in 4% PFA (20 min), and a postfixation in prechilled Ethanol:Acetic acid (2:1) (−20°C, 10 min). TUNEL staining was performed by using the ApopTag Peroxidase in situ apoptosis detection kit (S7100, Chemicon) according to the manufacturer\'s instructions. TUNEL-positive cells were labeled by incubating the embryos in 3-3′-diaminobenzidine tetrahydrochloride (DAB).

### Morpholinos {#s4-4-8}

Antisense oligos (morpholinos) targeting Spop were synthesized by Gene Tools (Corvalis, OR, United States). Morpholino 5 (MO5) was targeted to the sequence flanking the border between intron 1 and exon 2. Morpholino 7 (MO7) was targeted to the sequence flanking the border between intron 2 and exon 3. Morpholino sequences are shown in [Supplementary file 1](#SD3-data){ref-type="supplementary-material"}. Morpholino antisense oligos were dissolved in water to a final concentration of 1 mM. Primers used to validate morpholino-induced splicing of Spop are shown in [Supplementary file 1](#SD3-data){ref-type="supplementary-material"}.

### Plasmids {#s4-4-9}

For the generation of pLenti SPOP expression vectors, mutant or SPOP WT was TOPO TA-cloned from pCMV-SPOP vectors ([@bib4]) into pLenti viral vectors (pLenti6/V5-Dest Gateway Vector, V496-10, Invitrogen). For SPOP mRNA, in vitro transcription SPOP cDNA was TOPO TA cloned into a pCR 8 TOPO TA Gateway entry vector by using the pCR 8/GW/TOPO TA cloning kit (K2500-20, Invitrogen). 3-way-gateway recombination was then performed by using LR clonase II (11791, Invitrogen) to recombine SPOP cDNA from the pCR 8 TOPO TA gateway middle entry vector into a pDestTol2pA2 attR4-R3 (\#394) destination vector. The 5′ entry clone was (p5E-CMV/SP6, \#382) and the 3′ entry clone was (p3E-poly A, \#302). The final vector contains a SP6 site for subsequent in vitro mRNA transcription.

### In vitro mRNA transcription {#s4-4-10}

Human SPOP mRNA for rescue experiments in the zebrafish was generated using the mMessage mMachine SP6 kit (AM1340, Life Technologies) according to the manufacturer\'s instructions. RNA was analyzed quantitatively and qualitatively using the Agilent 2100 bioanalyzer.

### RNA sequencing {#s4-4-11}

RNA was isolated from zebrafish embryos at 24 hpf using Trizol. 50 water- or morpholino-injected embryos were used. RNA libraries were created and sequenced using the GA2X or HighSeq genome analyzer (Illumina, United Kingdom) as described previously ([@bib4]). The files first underwent quality control using FASTQC (v2_1.2.10). The vast majority of the reads from all the samples were of good quality (phred quality score \>30). Therefore, no trimming or filtering of reads was required. The reads were then aligned with STAR (v2.3.0e) to zebrafish reference genome (Zv9).

Bioinformatic analyses {#s4-5}
----------------------

Genomic analysis: SCNA profiles for 402 prostate cancers were obtained through processing of high-density oligonucleotide array data upon signal segmentation and then combined for genome-wide analysis for *SPOP* mutant and *SPOP* wild-type tumors. Clonality analysis for selected lesions was performed from sequencing data as in [@bib3].

Differential Gene Expression (DGE) and Gene Set Enrichment Analysis: After sorting and indexing, the aligned files were used with bedtools (v2.16.1) and Ensembl Zebrafish Transcriptome (v70) to generate read counts for genes for all samples. These read counts were used with DESeq (2_1.2.10) for differential expression. Orthology was also added to the differential expression table in this step. Read counts were also counts per million (cpm) normalized using EdgeR (v3.4.2) package and then pre-ranked using Log2 Fold Change. GSEA (v2-2.0.13) was run in pre-ranked mode to identify enriched signatures. Primers used for validation of the expression of selected genes are shown in [Supplementary file 1](#SD3-data){ref-type="supplementary-material"}.

Human samples {#s4-6}
-------------

Clinically localized prostate cancers were selected for transcriptome sequencing as described ([@bib4]). All samples were collected with informed consent of the patients and prior approval of the institutional review boards (IRB) of respective institutions. Additionally, the sequencing and data release of all transcriptome-sequenced samples was reviewed and approved by local IRB.

### Statistics {#s4-6-1}

The results are represented as means of at least three experiments (standard error of the mean (s.e.m.) are indicated by error bars). Student\'s *t-*test was used to calculate the statistical significance of differences in the HR- and NHEJ-reporter assays. Fisher\'s exact test (two sided) was used to assess the statistical significance of differences in the foci assays. Nonlinear regression was performed to determine the IC50 values in the in vitro drug sensitivity assays.

Accession codes {#s4-7}
---------------

All RNA-seq data are deposited in the NCBI sequencing read archive (SRA) under the accession number SRP063952.
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Sequences of antisense-morpholino\'s targeting Spop as well as primers used in this study.

**DOI:** [http://dx.doi.org/10.7554/eLife.09207.024](10.7554/eLife.09207.024)

Major dataset {#s6-1}
-------------

The following previously published dataset was used:

2012,Prostate Cancer Genome Sequencing Project,<http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000447.v1.p1>,Publicly available at the NCBI (Accession no: phs000447.v1.p1).
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for submitting your work entitled "*SPOP* mutation leads to genomic instability in prostate cancer" for peer review at *eLife*. Your submission has been favorably evaluated by Charles Sawyers (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The reviewers considered this manuscript very well written, interesting, and potentially very important for a number of reasons. The manuscript describes the characterization of *SPOP* mutations in prostate cancers and reveals a new role for SPOP in the DNA damage repair response (DDR). While analyzing data on chromosomal rearrangements and mutational status of hundreds of prostate cancers, the authors make the interesting observation that 'high rearrangement' correlates with *SPOP* mutations. They go on to show that SPOP is involved in late steps of the DDR response, and that *SPOP* mutations impair homologous recombination (HR) and favor error-prone non-homologous end-joining (NEHJ), which could potentially explain the correlation between *SPOP* mutations and high frequency of rearrangements. This function resembles that of the DDR factor BRCA1. In fact, *SPOP* mutations also seem to be mutually exclusive with *BRCA1* mutations. Finally, the authors show some data suggesting that *SPOP* mutations may sensitize cells to PARP inhibitors, which have been shown to be synthetic lethal with *BRCA1* mutations.

The reviewers considered the manuscript to be potentially meritorious for publication in *eLife* after addressing some major concerns:

1\) The data supporting the conclusion that *SPOP* mutations sensitize cancer cells to PARP inhibitors is currently very weak, based solely on the analysis of RWPE primary prostate cells, RR2v1 prostate cancer cells and embryonic kidney cells (HEK) using artifact-prone overexpression experiments. The conclusion that *SPOP* mutations could be synthetic lethal with PARP inhibition could have profound implications in the clinic and therefore must be exhaustively tested by the authors. Toward this end, the following experiments are requested:

1.1) PARP inhibitors should be tested in a dose-response experiment in prostate cancer cell lines expressing wild type or mutant SPOP. We recognize that this request may be challenging due to the limited number of prostate cancer cell lines but we would like to see if the prediction holds in whatever models may be available.

1.2) The authors should establish an isogenic system using a prostate cancer cell line of choice currently expressing wild type SPOP and thus resistant to PARP inhibitors, and either knockdown or knock-out SPOP and demonstrate that SPOP depletion is sufficient to confer sensitivity.

2\) Can the authors account for the discrepancy between their data and the previously published work by Zhang et al. (Carcinogenesis 35: 1691, 2014)? This paper shows that SPOP is required for the DDR. Accordingly, Boysen et al. should also test whether SPOP localizes to DSBs following IR and they should more thoroughly present their own DDR data, even though their results were negative.

3\) The manuscript begins with examination of WGS data from 55 treatment naïve prostate cancers and subsequent distribution into 2 chromosomal rearrangement populations -- "low-rearrangement" and "high-rearrangement". The "high-rearrangement" group was significantly associated with *SPOP* mutations, but also with recurrent deletions on 5q and 6q, containing the tumor suppressors CHD1 and MAP3K7. Because of clonality studies the authors pursue the role of *SPOP* mutations only. Though the data regarding contribution of *SPOP* mutation to DNA damage response and sensitivity to PARP inhibitors are convincing, no attempt is made to see whether losses at 5q and 6q contribute to this phenotype independently or cooperatively with *SPOP* mutation. 5q CNAs, specifically loss of CHD1, have been implicated in high chromosomal rearrangements, and MAP3K7 is also highly correlated with chromosomal rearrangements. Examining the 5q and 6q status of the patients in [Figure 2F](#fig2){ref-type="fig"}, either alone or in combination with *SPOP* mutant status would be informative and provide a clearer understanding of the contributions of these genes to the DNA damage phenotype (*BRCA1* mutant gene set) of this subtype. It would be informative to see how these CNAs co-segregate.

4\) The paper does not provide a molecular mechanism. Specifically, recent studies by Theurillat et al. indicate that mutations in *SPOP*, an E3 substrate binding protein, results in upregulation of specific protein substrates (DEK, TRIM24, for example) via a dominant negative mechanism. But this new study by Boyser et al. does not provide a mechanism of disrupted HR. Is SPOP inhibiting the degradation of some critical substrate which is causing the transcriptional response consistent with *BRCA1* inactivation? Can the authors provide any additional data in this regard?

Minor comments \[abridged\]:

1\) The authors conclude that phosphorylation of ATR is not affected by *SPOP* mutations, but the blots in [Figure 3--figure supplement 1F and H](#fig3s1){ref-type="fig"} are discordant in this sense. Please repeat with several biological replicates to define this issue.

2\) In the zebrafish experiments, SPOP knockdown leads to cell death concurrently with induction of p53 mRNA and induced expression of the p53 target genes *MDM2* and *CCNG1*. The authors should comment on this, acknowledging that cell death could be due to p53 activation in this setting.

3\) A recent study indicates that a high percentage (15-20%) of metastatic CRPC have underlying mutations in DNA repair genes (*BRCA2* and *ATM* most commonly). The authors show some TGCA data for *BRCA1*. Are these mutations in CRPC (i.e. *BRCA2* and *ATM*) mutually exclusive with *SPOP* mutations?

10.7554/eLife.09207.026

Author response

*1) The data supporting the conclusion that* SPOP *mutations sensitize cancer cells to PARP inhibitors is currently very weak, based solely on the analysis of RWPE primary prostate cells, 22Rv1 prostate cancer cells and embryonic kidney cells (HEK) using artifact-prone overexpression experiments. The conclusion that* SPOP *mutations could be synthetic lethal with PARP inhibition could have profound implications in the clinic and therefore must be exhaustively tested by the authors. Toward this end, the following experiments are requested*:

*1.1) PARP inhibitors should be tested in a dose-response experiment in prostate cancer cell lines expressing wild type or mutant SPOP. We recognize that this request may be challenging due to the limited number of prostate cancer cell lines but we would like to see if the prediction holds in whatever models may be available*.

We concur that the implications of *SPOP* mutant cancers as a target for PARP inhibition is potentially important. We initially sought prostate cancer cell line models that harbor the *SPOP* mutation but unfortunately there are none to our knowledge. We also recognize the limitations of overexpressing mutant SPOP in the 22Rv1 prostate cancer cell lines as a model system. Therefore to address this issue, we developed a model system expressing inducible mutant SPOP in mouse prostate organoids. These are derived from a genetically engineered mouse model expressing SPOP-F133V in a Cre dependent manner, using a knock-in to the *Rosa26* locus (manuscript in preparation). The protein expression levels of mutant SPOP are approximately the same as endogenous SPOP in this model, mimicking human tumors ([Figure 3--figure supplement 2](#fig3s2){ref-type="fig"}), and originally utilizing this model ([Figure 3](#fig3){ref-type="fig"}, [Figure 5](#fig5){ref-type="fig"}). We have expanded the series of experiments examining PARP inhibitor sensitivity in this mouse organoid model. In new dose response experiments suggested by the reviewer, expression of physiologically relevant levels of mutant SPOP led to increased sensitivity to olaparib compared to control cells ([Figure 5D](#fig5){ref-type="fig"}).

*1.2) The authors should establish an isogenic system using a prostate cancer cell line of choice currently expressing wild type SPOP and thus resistant to PARP inhibitors, and either knockdown or knock-out SPOP and demonstrate that SPOP depletion is sufficient to confer sensitivity*.

In the initial submission, we presented limited data showing that knockdown of *SPOP*, similar to knockdown of *BRCA1*, sensitized 22Rv1 prostate cancer cells to PARP inhibition ([Figure 5G](#fig5){ref-type="fig"}). We have now expanded the series of experiments examining PARP inhibitor sensitivity with *SPOP* knockdown in our model systems. *SPOP* knockdown resulted in increased sensitivity to PARP inhibition in three prostate cell lines (22Rv1, PC3, and LNCaP) ([Figure 5A-C](#fig5){ref-type="fig"}). This effect was observed using two PARP inhibitors (i.e. olaparib, veliparib).

While these experiments do support the proposed role of SPOP in DSB repair, they should be interpreted with caution, since deletion of *SPOP* is not observed in human prostate cancer, and therefore may not phenocopy *SPOP* mutation in all models.

*2) Can the authors account for the discrepancy between their data and the previously published work by Zhang et al. (Carcinogenesis 35: 1691, 2014)? This paper shows that SPOP is required for the DDR. Accordingly, Boysen et al. should also test whether SPOP localizes to DSBs following IR and they should more thoroughly present their own DDR data, even though their results were negative*.

Zhang D. et al. proposed a role for SPOP in the DDR based primarily on co-localization with other DDR components, without focusing on cancer-derived *SPOP* mutations. Their paper showed that *SPOP* knockdown with siRNA potentially led to prolongation of DSB repair (as measured by γH2AX foci). While these studies examining the consequences of *SPOP* knockdown in other cell types are interesting, and suggest a role in the DDR, they were not examined in a prostate context, and *SPOP* mutations are highly specific to prostate cancer. The tissue context may account for some of the differences between our results. We agree with the reviewers that determining localization of SPOP following γ-irradiation (IR) and co-localization with DNA repair complexes in a prostate context is important. Using immunofluorescence, we show that SPOP has increased nuclear foci following IR in both mouse and human prostate cells ([Figure 3A](#fig3){ref-type="fig"}).

In addition, we show that SPOP has only limited co-localization with γH2AX and phospho-ATM, following IR in prostate cells -- this co-localization was not affected by expression of mutant SPOP ([Figure 3--figure supplement 1I](#fig3s1){ref-type="fig"}).

These additional experiments support that SPOP plays a role in responding to DSB. However, the differences in co-localization compared to those reported by Zhang et al. may be due to tissue context. Further mechanistic experiments will be necessary (and are ongoing) to define the role of SPOP and impact of prostate cancer derived *SPOP* mutations.

*3) The manuscript begins with examination of WGS data from 55 treatment naïve prostate cancers and subsequent distribution into 2 chromosomal rearrangement populations -- "low-rearrangement" and "high-rearrangement". The "high-rearrangement" group was significantly associated with* SPOP *mutations, but also with recurrent deletions on 5q and 6q, containing the tumor suppressors CHD1 and MAP3K7. Because of clonality studies the authors pursue the role of* SPOP *mutations only. Though the data regarding contribution of* SPOP *mutation to DNA damage response and sensitivity to PARP inhibitors are convincing, no attempt is made to see whether losses at 5q and 6q contribute to this phenotype independently or cooperatively with* SPOP *mutation. 5q CNAs, specifically loss of CHD1, have been implicated in high chromosomal rearrangements, and MAP3K7 is also highly correlated with chromosomal rearrangements. Examining the 5q and 6q status of the patients in* [*Figure 2F*](#fig2){ref-type="fig"}*, either alone or in combination with* SPOP *mutant status would be informative and provide a clearer understanding of the contributions of these genes to the DNA damage phenotype (*BRCA1 *mutant gene set) of this subtype. It would be informative to see how these CNAs co-segregate.*

*SPOP* mutations, and deletions of 5q21 (CHD1) and 6q (MAP3K7) are highly associated, and together constitute a distinct molecular class of prostate cancer. The observation that all of these alterations were associated with increased genomic rearrangements suggests that this represents a genomically unstable molecular class of prostate cancer. To prioritize alterations for functional study, we used two points of rationale:

A\) Because the phenotype in question is structural genomic rearrangements, genomic deletions (such as CHD1 and MAP3K7) could be causative or consequences of this phenotype, since they result from structural rearrangements. Point mutations (such as *SPOP*) cannot be a consequence of deregulated genomic rearrangements.

B\) We therefore examined clonality data to determine the earliest event in this class (and therefore possibly the initiator of genomic instability, leading to subsequent genomic deletions), which prioritized *SPOP* mutation for functional study.

We appreciate the reviewers' comment and understand that a better exposition of these ideas will improve the message of the manuscript. We have therefore added the following computational analyses and annotation:

A\) To address the reviewers' comments, we have now extended the genomic analysis to include the official TCGA-PRAD (prostate adenocarcinoma) dataset of 333 patients. The revised data for the copy number analysis include a total of 430 patients of which 47 harbor a *SPOP* mutation. As originally reported, deletions on 5q21.1 and 6q15, spanning *CHD1* and *MAP3K7* respectively, are significantly concurrent with mutations in *SPOP* ([Figure 1--figure supplement 3](#fig1s3){ref-type="fig"}). When comparing individually *CHD1* deletions, *MAP3K7* deletions, and *SPOP* mutations, we did not observe significant differences in genomic burden for any one lesion ([Figure 1--figure supplement 4](#fig1s4){ref-type="fig"}).

B\) Figure panel 1F has now been updated with this larger set. The clonality fraction for *SPOP* mutation, *CHD1* deletion and *MAP3K7* deletion are 93.2%, 66.3%, and 88.1%, respectively.

C\) Further, we studied the dependencies of the 3 lesions using the larger dataset. The data still supports *SPOP* mutations preceding CHD1 ([Figure 1--figure supplement 5](#fig1s5){ref-type="fig"}). These observations are based on algorithm we developed to build tumor evolution paths ([@bib3]; [@bib26]).

D\) To specifically query the contribution of *CHD1* and *MAP3K7* deletions to the DNA damage phenotype, we included the deletion status in the annotation panel of the dendrogram from [Figure 2F](#fig2){ref-type="fig"}. The cluster enrichment for *CHD1* deletion is borderline significant (in line with the strong association with *SPOP* mutations); no signal is detected for *MAP3K7*. We favor the inclusion of this panel as [Figure 2--figure supplement 3](#fig2s3){ref-type="fig"} while maintaining *SPOP* annotation only in [Figure 2](#fig2){ref-type="fig"} as it is the focus of the study.

*4) The paper does not provide a molecular mechanism. Specifically, recent studies by Theurillat et al*. *indicate that mutations in* SPOP*, an E3 substrate binding protein, results in upregulation of specific protein substrates (DEK, TRIM24, for example) via a dominant negative mechanism. But this new study by Boyser et al. does not provide a mechanism of disrupted HR. Is SPOP inhibiting the degradation of some critical substrate which is causing the transcriptional response consistent with* BRCA1 *inactivation? Can the authors provide any additional data in this regard?*

In this current manuscript we focus on the biologic implications of *SPOP* mutations in the prostate cancer context. We agree wholeheartedly that the biochemical mechanism by which SPOP regulates DNA repair is a critical question for the field going forward. Defining the specific substrates potentially responsible for this biology will be a long process. For instance, BRCA1 is also a ubiquitin ligase clearly critical for DNA repair, yet the specific substrate of BRCA1 responsible for this function remains poorly defined over a decade after its discovery. This goal will require long-term mechanistic efforts outside the scope of the current manuscript.

Minor comments \[abridged\]:

*1) The authors conclude that phosphorylation of ATR is not affected by SPOP mutations, but the blots in* [*Figure 3--figure supplement 1F and H*](#fig3s1){ref-type="fig"} *are discordant in this sense. Please repeat with several biological replicates to define this issue*.

The results presented originally were representative of at least three biological replicates ([Author response image 1](#fig7){ref-type="fig"}). We found ATR phosphorylation in this experiment to be highly variable, especially in the 22Rv1 cell line -- however, there was no consistent effect of SPOP siRNA or ectopic expression of wt or mutant SPOP on ATR phosphorylation.10.7554/eLife.09207.027Author response image 1.**DOI:** [http://dx.doi.org/10.7554/eLife.09207.027](10.7554/eLife.09207.027)

*2) In the zebrafish experiments, SPOP knockdown leads to cell death concurrently with induction of p53 mRNA and induced expression of the p53 target genes* MDM2 *and* CCNG1*. The authors should comment on this, acknowledging that cell death could be due to p53 activation in this setting*.

The reviewers correctly note that SPOP knockdown triggered a transcriptional response similar to p53 activation. The developmental phenotype resulting from this knockdown was observed with two different SPOP morpholinos and was rescued with human wildtype SPOP mRNA suggesting a SPOP-specific effect. Interestingly, mutations in *SPOP* and p53 are mutual exclusive in localized prostate cancer ([@bib4]), further supporting a potential relationship. We agree with the reviewers, and have acknowledged the p53 activation in the text of the results section.

*3) A recent study indicates that a high percentage (15-20%) of metastatic CRPC have underlying mutations in DNA repair genes (*BRCA2 *and* ATM *most commonly). The authors show some TGCA data for* BRCA1*. Are these mutations in CRPC (i.e.* BRCA2 *and* ATM*) mutually exclusive with* SPOP *mutations?*

The reviewers pose an excellent question -- mutual exclusivity between *SPOP* mutations and *BRCA2* and *ATM* mutations described in the SU2C/PCF cohort (Robinson et al., Cell 2015) of CRPC samples would support a continued role of SPOP mutation in compromised DNA repair in CRPC.

As shown below ([Author response image 2](#fig8){ref-type="fig"}), no CRPC samples harbor both *SPOP* mutation and *ATM* mutations. Two cancers showed both *SPOP* mutation and *BRCA2* mutation, and one sample had both an *ATM* mutation and *BRCA2* mutation. The sample size (n=150 total) and event rates preclude meaningful statistical analysis (all p-values non significant for analysis (all p-values non significant for analysis mutual exclusivity). We have added this analysis to [Figure 2--figure supplement 4B](#fig2s4){ref-type="fig"}.10.7554/eLife.09207.028Author response image 2.**DOI:** [http://dx.doi.org/10.7554/eLife.09207.028](10.7554/eLife.09207.028)
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